You are here

  • Home
  • Online First
  • Malignant biliary obstruction and percutaneous drainage: MELD score and survival prediction

Article Text

Article menu
Download PDFPDF
Letter
Malignant biliary obstruction and percutaneous drainage: MELD score and survival prediction
  1. Alia Alawneh1,
  2. Fadi Abu Farsakh2,
  3. Ayoub Innabi3 and
  4. Wael Tuqan4
  1. 1Internal medicine, Jordan University of Science and Technology, Irbid, Jordan
  2. 2Palliative medicine department, King Hussein Cancer Center, Amman, Jordan
  3. 3Palliative medicine department, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
  4. 4Gastroenterology, Ochsner Medical Center - New Orleans, Jefferson, Louisiana, USA
  1. Correspondence to Dr Alia Alawneh, Internal medicine, Jordan University of Science and Technology, Irbid 22110, Jordan; aaalawneh8{at}just.edu.jo

https://doi.org/10.1136/spcare-2022-003826

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Malignant biliary obstruction (MBO) is a debilitating condition that affects significantly the quality of life by causing anorexia, fatigue and pruritus, it can also interfere with the administration of palliative chemotherapy. Unfortunately, patients with MBO often present at a late stage of their illness and treatment usually focuses on reliving the symptoms. The optimal intervention for MBO is internal drainage by placement of metallic stent. For patients in whom endoscopic intervention is not feasible, a percutaneous transhepatic biliary dilatation (PTBD) by interventional radiologist is preferred. PTBD was found to improve pruritus and often reduces hyperbilirubinaemia to a level that does not contraindicate the administration of chemotherapy; however, PTBD is associated with a significant rate of complications, which may impair patients’ quality of life. In addition, patients often have poor prognosis which may not allow them to benefit from the intervention. Therefore, a prognostic model of survival is needed for this subgroup of patients to help healthcare providers and patients make an informed decision regarding this procedure. In a previous study,1 we aimed to identify the predictive factors of survival in MBO post PTBD, presence of ascites was a significant prognostic …

    View Full Text

    Footnotes

    • Contributors AA contributed to study design, data analysis and manuscript writing. FAF contributed to study design, data collection and analysis. AI contributed to study design, data collection and analysis. WT contributed to study design, data collection and analysis.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.